RxDoctor Payments Data

Quin Bixler, MD

Obstetrics & Gynecology · Mobile, ALNPI 1326347220

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Bayer at 54.0% of the total. Reporting peaked in 2019 at $5,112 and has fallen 78.7% since, to $1,088 in 2025. Among obstetrics & gynecology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,019in general payments, 2019–2025

Across 339 payments — averaging $35.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$6K
  • AbbVie$669
  • Mayne Pharma Commercial LLC$612
  • Astellas Pharma US Inc$590
  • Intuitive Surgical$478
  • Pfizer$392
  • plus $3K from 42 others

What the payments were for

  • Speaking & faculty fees$5,98050%
  • Food & beverage$5,91949%
  • Education$1201%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,019 in reported general payments places this provider in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,347
Medicare patients
23
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$10,989
PremarinEstrogens, Conjugated18$9,889
Estradiol110$1,545
Medroxyprogesterone Acetate42$630
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$247
Oxybutynin Chloride ErOxybutynin Chloride11$228
Fluconazole17$157
Alprazolam11$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$590$10,98913 claims
PfizerPremarin$392$9,88918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →